Recent Company News

• 07:08 AM ET Sep 29, 2025
  

  BioLineRx and Hemispherian announce JV to develop GLIX1, targeting DNA damage response in glioblastoma and other cancers (2.10a, 0.00)

• 07:01 AM ET Sep 29, 2025
  

  BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

• 07:08 AM ET Aug 14, 2025
  

  BioLineRx reports Q2 EPS ($0.00) vs FactSet $0.00 [3 est, ($0.00)-0.00] (2.20a, +0.10)

• 08:55 AM ET Apr 02, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:37 AM ET May 30, 2025
  

  BioLineRx upgraded to buy from hold at Jones ($3.79, 0.00)

• 07:04 AM ET May 30, 2025
  

  BioLineRx announces new pilot phase data from Phase 2 combination trial of motixafortide in first line PDAC to be presented at ASCO (2.20a, 0.00)

• 07:06 AM ET May 27, 2025
  

  BioLineRx reports Q1 EPS $0.00 vs FactSet $0.00 [2 est, ($0.00)-(0.00)] (2.20a, 0.00)

• 04:57 PM ET Apr 01, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market